Description
Tirzepatide 10mg — dual GLP-1/GIP receptor agonist for metabolic research in Australia. University-verified ≥99% purity. Same-day Sydney dispatch.
Tirzepatide is a 39-amino acid synthetic peptide that activates both GLP-1 and GIP receptors. FDA-approved as Mounjaro and Zepbound, it represents a new class of dual incretin agonists with extensive clinical trial data.
What the Research Shows
Research has documented Tirzepatide’s effects on glucose homeostasis, insulin secretion, and body weight regulation. The dual receptor mechanism provides enhanced metabolic effects compared to GLP-1-only agonists.
Phase 3 trials (SURPASS and SURMOUNT programs) provide comprehensive data on efficacy and safety. Published literature documents dose-response relationships and pharmacokinetic profiles.
Why Australian Researchers Choose Purpose Labs
Every batch is tested at a leading Australian university — HPLC and mass spectrometry confirm ≥99% purity. No generic overseas certificates.
→ Explore the Peptide Research Library
Purity: ≥99% (HPLC)
Form: Lyophilised powder
Molecular Weight: 4813.45 Da
CAS: 2023788-19-2
Targets: GLP-1R / GIPR
Research: PubMed
▸ Australian university verified
▸ ≥99% purity guaranteed
▸ Same-day dispatch from Sydney
▸ Research-grade lyophilised powder
Related Research and Resources
For research use only. Not for human consumption.




